THC/CBD spray improved quality of life in a patient with stiff-person syndrome | Research

The takeaway

A patient with stiff-person syndrome who had not responded to standard treatments showed improvement across all quality of life dimensions after 14 months of THC/CBD oral spray.

Read this if you are interested in cannabinoid therapy for rare neurological conditions involving muscle rigidity.

Improvement across all 8 quality of life dimensions after 14 months of treatment

What the researchers found

A 40-year-old man with seronegative stiff-person syndrome (SPS), a rare disorder causing progressive muscle rigidity and painful spasms, had not responded adequately to standard treatments. After starting THC/CBD oromucosal spray (Sativex), he showed improvement across all eight dimensions of the SF-36 quality of life questionnaire at the 14-month follow-up.

SPS is diagnosed based on clinical features and continuous motor unit activity on electrophysiology testing. This patient tested negative for glutamic acid decarboxylase (GAD) antibodies in both blood and cerebrospinal fluid, classifying him as seronegative.

Why it matters

Stiff-person syndrome is rare and difficult to treat. When standard therapies fail, clinicians have limited options. This case report documented a potential role for cannabinoid-based therapy in managing SPS symptoms, though it represents only a single patient experience.

The numbers in context

One patient, age 40, with six years of symptoms. Treatment duration was 14 months. Improvement was documented across all eight SF-36 quality of life dimensions.

How the study worked

Single case report describing a 40-year-old male with a six-year history of progressive muscle stiffness and intermittent spasms. After multiple unsuccessful standard treatments, THC/CBD oromucosal spray was introduced. Quality of life was assessed using the SF-36 questionnaire at baseline and after 14 months of treatment.

What this study cannot tell us

This is a single case report with no control comparison. Placebo effects, natural disease fluctuation, and concurrent treatments could all contribute to the observed improvement. SF-36 is a subjective quality of life measure. The findings cannot be generalized without controlled trials.

How to read the evidence

Single case report. Interesting but cannot establish efficacy without controlled trials.

When this study was published

Published in 2013. Stiff-person syndrome remains rare, and controlled trials of cannabinoid therapy for SPS are limited.

The bigger picture

Both multiple sclerosis and stiff-person syndrome involve spasticity and rigidity. Since THC/CBD spray was already approved for MS-related spasticity in some countries, this case suggested the benefits might extend to other conditions with similar neurological symptoms.

Questions still open

Would controlled trials of THC/CBD spray in SPS patients confirm these results? Does the seronegative subtype of SPS respond differently to cannabinoid therapy than GAD-positive SPS? What is the mechanism by which cannabinoids might affect muscle rigidity in SPS?

Common questions

What is stiff-person syndrome?

A rare neurological disorder causing progressive muscle rigidity and painful spasms, typically involving the trunk and limbs. It is often treated with benzodiazepines, baclofen, and immunosuppressants.

Can cannabis treat stiff-person syndrome?

This single case report showed improvement with THC/CBD spray, but one patient does not constitute evidence of efficacy. Controlled trials would be needed to determine whether this approach works reliably.

Read the original research

Cannabis derivatives therapy for a seronegative stiff-person syndrome: a case report.

Journal of clinical pharmacy and therapeutics, 38(1), 71-3

View on PubMed ↗Publisher’s paper ↗

Citation

Vicente-Valor, M I; Garcia-Llopis, P; Mejia Andujar, L; Antonino de la Camara, G; García del Busto, N; Lopez Tinoco, M J; Quintana Vergara, B; Peiro Vilaplana, C; Dominguez Moran, J A; Sánchez Alcaraz, A. (2013). Cannabis derivatives therapy for a seronegative stiff-person syndrome: a case report.. Journal of clinical pharmacy and therapeutics, 38(1), 71-3. https://doi.org/10.1111/j.1365-2710.2012.01365.x